U.S. markets open in 4 hours 56 minutes

Co-Diagnostics, Inc. (CODX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.58+0.32 (+3.46%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close9.26
Open9.35
Bid0.00 x 1800
Ask0.00 x 1200
Day's Range8.95 - 10.11
52 Week Range7.01 - 30.99
Volume1,645,744
Avg. Volume1,074,051
Market Cap276.669M
Beta (5Y Monthly)-1.97
PE Ratio (TTM)5.54
EPS (TTM)1.73
Earnings DateAug 11, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
34% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Co-Diagnostics Blasted 21% Higher on Thursday
    Motley Fool

    Why Co-Diagnostics Blasted 21% Higher on Thursday

    The roller-coaster-like trajectory that has been Co-Diagnostics' (NASDAQ: CODX) stock price climbed another hill on Thursday. Co-Diagnostics announced that its CoPrimer diagnostics platform, which underpins testing products -- like its popular-for-obvious-reasons Logix Smart for COVID-19 -- has been granted a patent in South Korea. "We believe that this patent granted by South Korea provides additional validation of the uniqueness and versatility of the CoPrimer platform," the company quoted CEO Dwight Egan as saying.

  • Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent
    PR Newswire

    Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent

    Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea's Intellectual Property Office for the Company's CoPrimer™ technology.

  • Co-Diagnostics, Inc. (CODX) Fell Out Of Favor With Hedge Funds
    Insider Monkey

    Co-Diagnostics, Inc. (CODX) Fell Out Of Favor With Hedge Funds

    In this article we will analyze whether Co-Diagnostics, Inc. (NASDAQ:CODX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into […]